Long-term effects of Aldara 5% cream and Solaraze 3% gel in the treatment of actinic keratoses on the face or scalp with respect to the risk of progression to in-situ and invasive squamous cell carcinoma (LEIDA 2)

Trial Profile

Long-term effects of Aldara 5% cream and Solaraze 3% gel in the treatment of actinic keratoses on the face or scalp with respect to the risk of progression to in-situ and invasive squamous cell carcinoma (LEIDA 2)

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Apr 2017

At a glance

  • Drugs Imiquimod (Primary) ; Diclofenac
  • Indications Actinic keratosis
  • Focus Therapeutic Use
  • Acronyms LEIDA-2
  • Sponsors Meda
  • Most Recent Events

    • 02 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 26 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 19 Oct 2011 New source identified and integrated (ClinicalTrials.gov NCT01453179).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top